Klaus S.

Klaus S. is an experienced finance professional specializing in investor relations, business development, and mergers and acquisitions. Currently serving as the Head of Investor Relations at Embla Medical since May 2024, Klaus previously held the same position at Hansa Biopharma from April 2019 to May 2024. A career at Novozymes lasted from 2006 to 2018, where Klaus progressed through roles such as Senior Manager in Investor Relations and Acquisition Manager, overseeing significant transactions including EMD CropBioscience for $283 million. Earlier professional experiences include roles as Business Development Director at Royal Unibrew, M&A Analyst at DSP Corporate Finance, Project Controller at TDC, and Auditor at Ernst & Young. Klaus S. holds a Master's degree in Finance from Copenhagen Business School and has completed further education at MIT Sloan School of Management, ICAEW, and Fudan University.